图片: | |
---|---|
名称: | |
描述: | |
淋巴瘤确实是个麻烦的东西,我前阵子碰到一个CD79a表达阳性的T淋巴母,半个月不到又碰到一个更麻烦的病例,患者颈部淋巴结肿大两年余,近2个月全身淋巴结肿大,免疫组化和形态学看是一个典型的弥漫大B细胞淋巴瘤,但是发现有部分散在细胞CD30阳性,细胞像R-S样,那些R-S样细胞CD15阴性,PAX-5阳性,oct-2和bob-1阴性。
CD79a表达阳性的T淋巴母不是很罕见啊,你查查文献,很多的。需要注意pan-T标记全阴性但CD79a阳性的T-LBL,是个大陷阱。
弥漫大B细胞淋巴瘤这样的病例也有啊,如果是老年人,这样的病例可以做EBER,看看是不是EBV阳性的老人年大B,这样的病例常出现R-S样细胞。当然富于H/T的大B也可以。当然grey zone 淋巴瘤也可以。
感谢 chenliu0552老师很好的发言!
的确如此,CD43不仅表达于多量T细胞淋巴瘤,还可以表达于一些B细胞淋巴瘤,如套细胞淋巴瘤、小淋巴细胞淋巴瘤/白血病、粒细胞肉瘤等等,甚至还可以表达于一些非肿瘤细胞。本例CD2,CD3,CD4,CD8,CD5,CD7均阴性,在这样的大细胞病变形态基础上,此时做CD43和细胞毒标记物只是寻找诊断ALCL的佐证,后来果然CD43和部分细胞毒标志物是阳性,对于“裸”免疫表型的ALCL,这一诊断思路也是WHO和许多文献推荐的,日常工作中也是我们也常常是这样做的。如果病变是在淋巴结内,HE是大细胞病变,且出现上述免疫表型,我想应该有许多病理医生就诊断了ALCL了。只是本例部位等临床特征特殊,诊断需要慎之又慎,但最后ALK-1也显示大细胞阳性,就增加了诊断的信心。
此病例是非常特殊,其表现为:
1)ALCL很少原发于骨组织,
2)肿瘤细胞免疫表型特殊, CD30+CD15+ALK-1+CD43+Perforin+, 而其他PanB细胞和PanT细胞的标记均为阴性。
3)楼主诊断ALCL主要根据是 ALK-1+, 很有说服力!
问题:
1)如何解释ALCL表达 CD15?
2)除了ALK-1+支持ALCL外, 还有那些是支持ALCL的病理诊断线索(包括形态学和 IHC标记)?
感谢分享!
关于第二个问题:
本例是大细胞病变;本例出现了“裸”免疫表型,这可在ALCL中出现;本例perforin阳性,支持是细胞毒性的大细胞淋巴瘤;大细胞同时表达CD30/CD15/ALK/细胞毒标志物,据目前文献报道,只有ALCL能解释;EBER阴性;临床影像学提示为溶骨性病变。。。
欢迎大家补充!
非常感谢金主任,抛砖引玉式的精彩剖析!
此病例是非常特殊,其表现为:
1)ALCL很少原发于骨组织,
2)肿瘤细胞免疫表型特殊, CD30+CD15+ALK-1+CD43+Perforin+, 而其他PanB细胞和PanT细胞的标记均为阴性。
3)楼主诊断ALCL主要根据是 ALK-1+, 很有说服力!
问题:
1)如何解释ALCL表达 CD15?
2)除了ALK-1+支持ALCL外, 还有那些是支持ALCL的病理诊断线索(包括形态学和 IHC标记)?
感谢分享!
谢谢金主任指教!
关于第一个问题,请看文献摘要:
IMPATH Inc., New York, NY 10019, USA. wojciech.gorczyca@impath.com The characteristic histologic features and immunophenotype are usually diagnostic and allow distinguishing CD30 positive T-cell lymphoma (including anaplastic large cell lymphoma) from classical Hodgkin's lymphoma. The latter differs by expression of CD15 and lack of CD45, pan-T antigens and ALK expression. We report nine cases of large cell hematopoietic neoplasms in which the neoplastic cells co-expressed CD30 and CD15, and had immunophenotypic and morphologic features of T-cell lymphoproliferative process. The average age of the CD15-positive group was 61.9 years; 6 cases occurred in men and 3 in women. The tumors were located in lymph nodes in 8 cases, and in liver in 1 case. Two cases expressed ALK protein. There were no statistically significant differences in phenotypic parameters between the CD15-positive and CD15-negative neoplasms (p>0.05). However, the CD15-positive group appeared to show a minor trend toward less positivity for EMA (44% versus 72%), ALK protein (22% versus 51%), and CD45RO (33.3% versus 83.3%, p=0.07), when compared to the typical CD15-negative neoplasms. In summary, although the co-expression of CD30 and CD15is typical for classical HL, it may be also present in a subset of peripheral T-cell neoplasms including ALK-positive anaplastic large cell lymphoma. Combined and sensible use of morphology and a broad immunophenotypic panel in cases with limited material and/or those with overlapping histologic patterns will best discriminate between HL and ALCL. It is incumbent upon the pathologist to distinguish between these two clinicopathologic entities, since treatment options and clinical outcomes differ. 本例特殊之处在于,本例ALCL同时表达了ALK和CD15,这还是非常少见的,但是ALK在HL中的表达更少见。CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis.
Source
Abstract
本例患者未查见淋巴结肿大,无肝脾肿大。其余标记物:大细胞显示CD2,CD3,CD4,CD8,CD5,EMA,TIA-1,GranB, oct, Bob1, EBER均阴性。
阳性的有CD30,CD15,CD43,ALK,perforin。
最终诊断为:ALK阳性的间变性大细胞淋巴瘤,淋巴组织细胞变异型。
拿出来的目的:本例始发于骨骼,临床提示脓肿或骨髓瘤,ALK阳性但EMA阴性,细胞毒只有一个标记阳性,本例CD4不阳性。因为CD30和CD15均有非肿瘤细胞阳性的情况,所以对于这个骨骼病例,细胞少而退变,因此最初没有信心诊断,但ALK一般不在非肿瘤细胞内阳性表达,所以最终还是诊断了ALCL。